B. Metzler seel. Sohn & Co. AG Makes New $3.75 Million Investment in AxoGen, Inc. $AXGN

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 81,098 AxoGen shares worth approximately $3.75 million, while institutional investors collectively own 80.29% of the company.
• Analyst sentiment remains positive, with nine Buy ratings, one Hold, and one Sell; AxoGen has a “Moderate Buy” consensus rating and a $51 average price target.
• AXGN shares rose 8.5% to open at $50.40, near their 12-month high, after the company reported quarterly revenue of $69.73 million and earnings of $0.12 per share, matching estimates. Insiders have sold about 95,003 shares worth $4.48 million over the past 90 days.

B. Metzler seel. Sohn & Co. AG bought a new position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 81,098 shares of the medical equipment provider's stock, valued at approximately $3,746,000. B. Metzler seel. Sohn & Co. AG owned about 0.15% of AxoGen as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of AXGN. Royal Bank of Canada grew its holdings in shares of AxoGen by 14.2% during the first quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider's stock worth $704,000 after purchasing an additional 4,723 shares during the last quarter. AQR Capital Management LLC boosted its holdings in AxoGen by 45.3% in the first quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider's stock valued at $442,000 after acquiring an additional 7,453 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in AxoGen by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider's stock worth $466,000 after purchasing an additional 1,057 shares during the period. Jones Financial Companies Lllp grew its position in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider's stock worth $194,000 after buying an additional 10,481 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of AxoGen by 37.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider's stock worth $4,113,000 after buying an additional 103,072 shares during the period. Institutional investors and hedge funds own 80.29% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AXGN. Weiss Ratings reissued a "sell (d-)" rating on shares of AxoGen in a research note on Friday, May 29th. Citizens Jmp lifted their price objective on AxoGen from $50.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 30th. Jefferies Financial Group restated a "buy" rating and set a $55.00 target price on shares of AxoGen in a report on Wednesday, July 29th. HC Wainwright boosted their target price on AxoGen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, Raymond James Financial restated an "outperform" rating and set a $48.00 price objective on shares of AxoGen in a report on Wednesday, April 29th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $51.00.

Insiders Place Their Bets

In other news, Director Kathy Johnson Weiler sold 14,150 shares of AxoGen stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Mcbride Wendell sold 13,353 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the transaction, the director directly owned 107,976 shares in the company, valued at $5,228,197.92. The trade was a 11.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 95,003 shares of company stock valued at $4,482,997 over the last 90 days. 2.44% of the stock is currently owned by insiders.

AxoGen Trading Up 8.5%

Shares of AxoGen stock opened at $50.40 on Friday. AxoGen, Inc. has a 12-month low of $13.64 and a 12-month high of $51.06. The stock has a market cap of $2.71 billion, a P/E ratio of -74.12 and a beta of 1.11. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. The business's 50 day moving average is $44.11 and its 200-day moving average is $38.96.

AxoGen (NASDAQ:AXGN - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, hitting analysts' consensus estimates of $0.12. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The business had revenue of $69.73 million for the quarter, compared to the consensus estimate of $67.10 million. Equities research analysts predict that AxoGen, Inc. will post -0.45 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source